Prestige Consumer Healthcare : Q4 2026 Prestige Consumer Healthcare Inc. Earnings Conference Call Presentation

Published: 2026-05-13 16:53:16 ET PBH

Published on 05/13/2026 at 04:53 pm EDT

CL cmm "

thera

tears

PrestigeConsumer

CLEAR

Full-Year Fiscal 2026 Results

May 14th, 2026

FY 26 and Performance Recap

Drivers of Portfolio Growth

Financial Overview

FY 27 Outlook & The Road Ahead

F U L L - Y E A R F Y 2 6 R E S U L T S

FY 26 Sales Highlights

Revenue of $1.089 billion, down 4.3% versus prior year

Eye care sales impacted by production volatility and capacity & quality upgrades

International segment impacted by eye care supply and distributor order patterns

Superior Earnings and FCF

Adjusted Gross Margin(2) of 55.6% approximately flat to prior year

Adjusted Diluted EPS(2) of $4.38 versus $4.52 prior year

Free Cash Flow(2) growth to $246.4 versus prior year

Disciplined Capital Allocation

$156 million in FY 26 share repurchases

(3)

Ending leverage of 2.6x

Acquisitions of Breathe Right® and LaCorium Health on track for fiscal 2027

Proven Ability to Execute Value Creation Strategy

Investing for Growth with Proven Brand-Building Playbook

Superior Business Attributes Enable Free Cash Flow

Scalable & Efficient Platform Supports Disciplined Capital Allocation

+2.9%

5-Yr CAGR

+6.2%

5-Yr CAGR

+2.9%

5-Yr CAGR

Revenue

Adj. EPS(2)

Adj. FCF(2)

Progress Made in 2026

FY 2027 Outlook

Eye Care supply ramp remains a strategic priority

Meaningful progress on integration of Pillar5 after first full quarter of ownership

Owned aseptic eye care facility proving to be

strategically valuable

Rigorous quality standards ensure consumer trust despite category headlines

Identifying and partnering with supplemental suppliers to

augment capacity

Continued capex prioritization to enhance supply quality and resilience

Anticipate sales improvement versus prior year as production ramps in FY27

Expect variable shipment patterns in FY27 given minimal safety stocks today

Building capacity to produce the majority of volume in-house over time

Strategic multi-year plan to return to category

leadership in Eye Care

Relentless Focus on Ensuring the Highest Quality Supply in Sterile Eye Care

F U L L - Y E A R F Y 2 6 R E S U L T S

Expanding Category Reach in Multiple Ways Sustained Share Gains

Defend Motion Sickness Leadership with Engaging Content

Market Share & YoY $ Sales Growth*

Accelerate Penetration in Nausea Category

#2 Brand

(5%)

Private Label

& Other

(2%)

+5%

~57%

Market Share*

Expand Relevance Through GLP-1 Tailwinds

Digital Activation Targeted HCP Programs

Best New Launch in Amazon Category

Gaining market share (+2.1pts L12W)* driven by strong E-Commerce performance

Successful innovation driving premiumization and sustained category expansion

* MULO+C+Amazon Adult Rectal Laxatives for 12 week period ended 3/22/26

Product Development Initiatives

Extend Brand Through Better Consumer Experience or Claims

Innovate Through Technology or Forms

New Categories Expansion

Skin Tags

GLP-1

friendly

GLP-1

friendly

Mental

Alertness

E-Commerce as a % of Net Sales*

Optimizing Content to Changing Consumer Behavior with AI Adoption

~16%

~18%

+4.5x

~14%

~11%

~4%

New Product Development

Seasonal Content

Brand Refresh

FY 19 FY 21 FY 23 FY 25 FY 26

Continued strong performance across E-Commerce business

*MULO+ Retail sales data and International

assumptions as of 3/22/26

F U L L - Y E A R F Y 2 6 R E S U L T S

(5.0%)

Revenue of $281.6 million, down 6.4% vs. prior year on an organic basis(1)

$281.6 $296.5

(7.7%)

$96.4 $104.4

(6.8%)

$1.23 $1.32

Adjusted EBITDA(2) of $96.4 million compared to

$104.4 million prior year

Revenue Adjusted EBITDA(2) Adjusted EPS(2)

(4.3%)

$1,088.7

$1,137.8

(5.5%)

$353.8 $374.5

(3.1%)

$4.38 $4.52

Adjusted Diluted EPS(2) of $1.23, down 6.8%

compared to $1.32 prior year

Full-Year

Dollar values in millions, except per share data.

Revenue Adjusted EBITDA(2)

Adjusted EPS(2)

FY 26

$ 1,088.7

605.2

55.6%

148.8

13.7%

113.1

10.4%

20.9

$ 322.3

29.6%

% Chg

(4.3%)

(4.6%)

(4.5%)

4.5%

(1.6%)

(7.7%)

3 Months Ended

12 Months Ended

FY 26 Comments

Q4 FY 26

$ 281.6

155.9

55.4%

35.1

12.5%

27.4

9.7%

5.4

$ 88.0

31.2%

% Chg

(5.0%)

(8.3%)

(5.2%)

1.3%

7.4%

(12.8%)

Q4 FY 25

FY 25

Revenue down 4.5% organically(1) versus prior

Total Revenue

Adj. Gross Profit(2)

% Margin

A&M

% Total Revenue

Adj. G&A(2)

% Total Revenue

D&A (ex. COGS)

Adj. Operating Income(2)

% Margin

Adj. Earnings Per Share(2)

Adj. EBITDA(2)

% Margin

$ 296.5

170.0

57.3%

37.0

12.5%

27.1

9.1%

5.1

$ 100.9

34.0%

$ 1.23

$ 1.32

$ 96.4

$ 104.4

34.2%

35.2%

$ 1,137.8

634.5

55.8%

155.7

13.7%

108.2

9.5%

21.3

$ 349.2

30.7%

$ 4.38

$ 4.52

$ 353.8

$ 374.5

32.5%

32.9%

year

North America segment impacted by limited Clear Eyes supply and order timing in prior year

International segment down 3% excluding foreign currency due to limited eye care supply

Strong E-Commerce growth continued

Adjusted Gross Margin(2) of 55.6%

(5.5%)

(3.1%)

A&M of 13.7% of Revenue, consistent with expectations

Adjusted G&A(2) of 10.4% of Revenue

Adjusted Diluted EPS(2) down 3.1% vs. PY

(7.7%)

(6.8%)

Dollar values in millions, except per share data Amounts may not add due to rounding

Free Cash Flow(2) & Net Leverage(3)

Key Attributes

Enabling Efficient Allocation

$243 $246

$239

$222

3.3x

2.8x 2.4x 2.6x

FY 23 FY 24 FY 25 FY 26

Dollar values in millions

Model with

Low Capital Expenditures

Leading Margin Profile

Long-Term Cash Tax Savings

Ongoing Focus on Profitability

Repurchased $156 million (2.3 million shares) in FY 26

Investing in eye care manufacturing capabilities via acquisition of Pillar5

Low leverage providing flexibility to pursue strategic M&A

Attractive Business Attributes Enable Robust Free Cash Flow Generation

Invest in Current Brands to Drive Organic Growth

Anticipate approximately

$900 million total

Free Cash Flow(4) 3

over the next three years enhancing shareholder value

Focused on Debt Reduction to Enhance Optionality

Prioritize Deleveraging Following Acquisition of Breathe Right®

Strategic Share Repurchases

Opportunistic Share Repurchases Only if Warranted

Pursue M&A That is Attractive to Shareholders

Continue to Assess, but Would Be Balanced Against Leverage

Strong Free Cash Flow Will Enabled Rapid Debt Reduction to Unlock Shareholder Value

F U L L - Y E A R F Y 2 6 R E S U L T S

Diversified Portfolio of Leading, Trusted Brands

Established Organic Growth Playbook

Superior Financial Profile Generating Consistent Cash Flow

Scalable Platform

Organic Growth Engine Reinforced by M&A

Prestige's Business Attributes & Execution Drive Superior Shareholder Value Creation

Top Line Trends

Revenues of $1,100 to $1,121 million

- Organic growth of approximately 1% to 3%

Continue to emphasize brand-building across a diverse, needs-based portfolio

Projecting improved shipment trends in eye care

Pending acquisitions not yet included

EPS

Adjusted Diluted EPS of $4.42 to $4.51(5), tracking sales growth

Gross margin relatively consistent to prior year

G&A reflects addition of Pillar5, normalized incentive comp

Free Cash Flow

Free Cash Flow(4) of $250 million or more

Expect to close Breathe Right® and LaCorium Health in June and July, respectively

Prioritizing debt reduction for the balance of fiscal 2027

M&A Strategy at Work: Portfolio-Enhancing Consumer Health Deals

Breathe Right® & Other OTC Brands

LaCorium Health

Other Loyalty Brands

~34%

~$200M Revenue

~66%

~10%

~20%

~$40M

Revenue

~70%

Leader in therapeutic

lip, skin, and foot care

#1 Category-Synonymous Brand with Global Reach

Iconic #1 brand synonymous with the nasal strip category and represents expansion into a new category for Prestige

Diversified portfolio of trusted, established brands with loyal consumer followings

Immediately accretive to Prestige's gross and EBITDA margins

Supports Prestige's long-term organic growth targets

$150 million estimated present value of future tax savings

Sustained double-digit top-line growth for over a decade

Anticipate revenue accretion via category tailwinds and brand expansion

Global platform across Australia & New Zealand (~75% of business), North America, Middle East, and Asia

Asset-light model providing robust cash flow generation

Leverage distribution network and other operating expertise for significant revenue and cost synergies

Disclaimer

Prestige Consumer Healthcare Inc. published this content on May 13, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 13, 2026 at 20:52 UTC.